Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MMV367 · 1 trial · 12 indications
Maximum effect of drug (maximum parasite killing rate). Emax used in the PK/PD model comes from the mean viable parasite elimination half-life of cohort 1 as estimated in the parasite viability report as Emax was not clearly observed in the cohort 2 parasitemia profiles.
Half Maximal Effective Concentration PK/PD dataset contains the individual information from all arms including date and time of inoculum administration, MMV367 dose; MMV367 plasma PK concentrations; total parasitemia counts by 18S qPCR; gametocytemia counts by pfs25, pfMGET and pfSBP-1 if relevant; and typical covariates such as age, body weight, height, sex and race, to build the model and derive outcome results.
MIC is defined as the concentration when drug killing equals the parasite growth, i.e., the time at which the minimum parasite concentration is observed. Calculated using the combined data from all doses/arms/groups in both period 1 and 2, as prespecified in section 10 of the Statistical Analysis Plan.
MPC90 is defined as the concentration at which the clearance effect is at 90% of the maximum. Calculated using the combined data from all doses/arms/groups in both period 1 and 2, as prespecified in section 10 of the Statistical Analysis Plan. PK/PD dataset contains the individual information from all arms including date and time of inoculum administration, MMV367 dose; MMV367 plasma PK concentrations; total parasitemia counts by 18S qPCR; gametocytemia counts by pfs25, pfMGET and pfSBP-1 if relevant; and typical covariates such as age, body weight, height, sex and race, to build the model and derive outcome results.
PRR48 is given as the reduction of values on log10 transformed scale. Only MMV\_MMV367\_22\_01 data was used. PRR48 provides an estimate of the efficacy of an anti-malarial treatment. It is the ratio of parasite density over a 48-hour period, estimated using the slope of the optimal fit of the log-linear relationship of parasitemia decay. Optimal fit is derived using geometric mean parasitemia data (i.e. 18S qPCR measuring all blood stage malaria parasites). The optimal fit of the log-linear parasitemia decay by time relationship is determined using left and right censoring to systematically remove potential lag and tail phases of parasitemia decay. PRR48 was calculated for each participant using daily PCR data. If the model fit was adequate (overall model p-value\<0.001), the slope and corresponding SE from the log-linear regression was used to calculate overall dose-specific PRR48. Participants without adequate model fits were excluded from all dose-specific PRR48 calculations.
| Arm | Type | Description |
|---|---|---|
| MMV367 3mg | EXPERIMENTAL | IBSM challenge and MMV367 Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes. Day 8 participants will be dosed with MMV367 when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL. Different doses of MMV367 will be administered across and within cohorts in order to effectively characterise the PK/PD relationship. Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and MMV367 concentration. Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 24, or earlier. |
| MMV367 5mg | EXPERIMENTAL | IBSM challenge and MMV367 Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes. Day 8 participants will be dosed with MMV367 when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL. Different doses of MMV367 will be administered across and within cohorts in order to effectively characterise the PK/PD relationship. Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and MMV367 concentration. Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 24, or earlier. |
| MMV367 10mg | EXPERIMENTAL | IBSM challenge and MMV367 Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes. Day 8 participants will be dosed with MMV367 when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL. Different doses of MMV367 will be administered across and within cohorts in order to effectively characterise the PK/PD relationship. Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and MMV367 concentration. Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 24, or earlier. |
| MMV367 20mg | EXPERIMENTAL | IBSM challenge and MMV367 Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes. Day 8 participants will be dosed with MMV367 when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL. Different doses of MMV367 will be administered across and within cohorts in order to effectively characterise the PK/PD relationship. Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and MMV367 concentration. Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 24, or earlier. |
| MMV367 90mg | EXPERIMENTAL | IBSM challenge and MMV367 Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes. Day 8 participants will be dosed with MMV367 when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL. Different doses of MMV367 will be administered across and within cohorts in order to effectively characterise the PK/PD relationship. Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and MMV367 concentration. Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 24, or earlier. |
| MMV367 1500mg | EXPERIMENTAL | IBSM challenge and MMV367 Up to 18 healthy, malaria naïve adult participants are planned to be enrolled into this study, in cohorts of up to six participants each. on Day 0 participants will be inoculated intravenously with approximately 2,800 viable P. falciparum-infected erythrocytes. Day 8 participants will be dosed with MMV367 when parasitaemia for the majority of participants is expected to be above 5,000 parasites/mL. Different doses of MMV367 will be administered across and within cohorts in order to effectively characterise the PK/PD relationship. Regular safety assessments will be performed and blood will be collected to monitor parasite clearance and MMV367 concentration. Participants will receive compulsory antimalarial rescue treatment with Riamet® (artemether/lumefantrine) on Day 24, or earlier. |
| Name | Type | Description |
|---|---|---|
| MMV367 3mg | DRUG | Single dose |
| P. falciparum IBSM infection | OTHER | Induced Blood Stage Malaria from infected erythrocytes. |
| MMV367 5mg | DRUG | Single dose |
| MMV367 10mg | DRUG | Single dose |
| MMV367 20mg | DRUG | Single dose |
| MMV367 90mg | DRUG | Single dose |
| MMV367 1500mg | DRUG | Single dose |
Inclusion Criteria: 1 Healthy adults aged 18 to 55 years inclusive who will be contactable and available for the duration of the trial and up to two weeks following the EOS visit. 2\. Total body weight greater than or equal to 50 kg, and a body mass index (BMI) within the range of 18 to 32 kg/m2 (...
Top 20 of 28 competitors
MMV367 is an investigational small molecule being developed for infections, specifically for malaria caused by Plasmodium falciparum. It is being studied as an antimalarial agent to treat blood stage P. falciparum infection.
MMV367 is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK.
MMV367 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1b trial has been completed.
MMV367 has one completed clinical trial, NCT05979207, a Phase 1b study evaluating its pharmacokinetics, pharmacodynamics, and safety in healthy adult volunteers experimentally infected with blood stage P. falciparum. The trial enrolled 12 participants in Australia.
MMV367 is a small molecule antimalarial that targets blood stage Plasmodium falciparum infection. It is being studied for its ability to clear parasitemia in infected individuals, though its specific molecular target has not been disclosed.
MMV367 is a unique investigational compound and is not known to be the same as any other marketed drug. It is being studied under its own name in clinical trials.